Physician profile

Dana E Knowlton

Family · Edna, TX

NPI 1326403254

$494.28

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$275.41

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $248.38 2021-2023 Ozempic, Rybelsus
Glaxosmithkline, LLC. $77.41 2022-2023 Shingrix, Arexvy
Lilly USA, LLC $63.55 2022-2023 Mounjaro
Pfizer INC. $35.75 2023
Teva Pharmaceuticals USA, INC. $27.10 2022
Averitas Pharma INC. $19.23 2023 Qutenza
Idorsia Pharmaceuticals US INC $13.54 2023 Quviviq
Organon LLC $9.32 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Dana E Knowlton

$494.28

in general payments reported 2019-2025

Years
2021-2023
Top company
Novo Nordisk INC

https://glasscript.com/doctor/11073769/dana-e-knowlton

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.